Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...
Pharmaceutical Technology on MSN
JPM26: BioNTech gears up for multiproduct oncology status by 2030
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...
BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.
With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...
Pfizer and BioNTech previously announced that their jointly developed COVID-19 vaccine showed over 90% effectiveness in preventing infection based on initial trial data, although scientists ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
3d
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan
BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback